Compugen Ltd (NASDAQ: CGEN) disclosed successful experimental data for CGEN-15027, a Compugen-discovered immune checkpoint target candidate. The experimental results include ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Compugen Ltd (CGEN) Reports In-Line Q3 Loss of 11c/ShareOctober 29, 2014 7:14 AM